BOC-D-valine (CAS 22838-58-4, C₁₀H₁₉NO₄, MW 217.26) is used in Boc-strategy solid-phase peptide synthesis for the introduction of D-Val residues. In a typical PAM or MBHA resin assembly, the monomer is dissolved in anhydrous DMF at 0.25 M to 0.40 M; the exact concentration is matched to the resin substitution capacity, which for PAM is usually 0.5–1.0 mmol/g. Pre-activation with HBTU (3.0 equiv relative to free amine) and DIPEA (6.0 equiv) is carried out for 3 min at 0–4°C before addition to the resin. Coupling proceeds at 25°C for 2 h under mechanical stirring at 50 rpm. The β-branched isopropyl side chain of D-valine imposes steric hindrance in couplings to N-methylated or α,α-disubstituted amines; if Kaiser ninhydrin testing remains positive, a second treatment with 2.0 equiv of fresh pre-activated BOC-D-valine for 1 h is applied. For sequences where HBTU-derived guanidine side products interfere with later ion-exchange purification, DIC/HOBt in DMF/DCM 1:1 is substituted, with coupling times of 6–12 h at 20–25°C.

Deprotection of the BOC group uses TFA/DCM 1:1 (v/v), 2 × 30 min, at 20°C. The resin is drained, washed with DCM, neutralized with DIEA/DMF 1:9 (v/v), and washed again. Cleavage from PAM resin is performed with liquid HF/anisole 9:1 at 0°C for 60 min in a Kel-F HF apparatus; MBHA resin cleavage uses TFMSA/TFA 1:9 at 0°C for 2 h. The crude D-Val-containing peptide is precipitated in cold diethyl ether, washed twice, and lyophilized from water/acetonitrile. The process is conducted under ICH Q7 and 21 CFR 210/211 when the peptide is an intermediate in an active pharmaceutical ingredient; residual TFA and fluoride are monitored in the lyophilized solid by ion chromatography and controlled against process-specific release limits.

How Does Solution-Phase Fragment Coupling of BOC-D-valine Avoid Racemization at Low Temperature?

In solution-phase fragment coupling, the mixed carbonic anhydride route is selected because the BOC urethane N-protection suppresses the direct formation of a free amino acid oxazolone. BOC-D-valine (1.0 equiv) is dissolved in anhydrous THF at 0.15 M and cooled to -20°C under nitrogen. N-methylmorpholine (1.1 equiv) is added in one portion, followed by isobutyl chloroformate (1.05 equiv) over 10 min. Stirring is continued for 15 min at -20°C; a white suspension of NMM·HCl forms. The cold mixed anhydride solution is then added through a dropping funnel to a solution of the hydrochloride salt of H-D-Ala-OMe (1.0 equiv) and NMM (1.1 equiv) in DMF at -10°C. The addition is controlled over 30 min, and the batch is warmed to 0–5°C over 1 h, then stirred for an additional 2 h at 22°C.

The reaction is quenched with 5% citric acid and extracted with ethyl acetate. The organic phase is washed sequentially with 0.5 M NaHCO₃ and saturated NaCl, dried over MgSO₄, and concentrated at 30°C under reduced pressure. The BOC group is removed with 4 M HCl in 1,4-dioxane at 0°C for 1 h; concentration followed by trituration with diethyl ether gives the D-Val-containing fragment hydrochloride. Racemization control is performed by chiral HPLC under USP <621> using a zwitterionic ion-exchange chiral stationary phase with methanol/water/formic acid 90:10:0.1 and UV detection at 210 nm. The D-Leu or L-Val impurity, when present, is integrated against a qualified reference standard. Residual THF and DCM are controlled by headspace gas chromatography per USP <467>; limits follow ICH Q3C Class 2 values of 720 ppm for THF and 600 ppm for DCM. The process is not suitable for scavenger-free deprotection in aqueous alkali because the BOC group requires acidolysis; base hydrolysis simultaneously risks opening of the terminal ester in the fragment.

The Oxazolidinone Route from D-Valinol Proceeds Through Two Discrete Activation Steps

BOC-D-valine is first converted to N-Boc-D-valinol to provide the 1,3-amino alcohol required for cyclic carbamate formation. A solution of BOC-D-valine (10.0 g, 46.0 mmol) in anhydrous THF (60 mL) is cooled to 0°C and treated dropwise with 1.0 M borane-tetrahydrofuran complex (115 mL, 115 mmol) over 30 min. After addition, the batch is warmed to 25°C and stirred for 18 h. Methanol (10 mL) is added at 0°C to quench residual borane; the solvent is evaporated, and the residue is partitioned between ethyl acetate and 1 M NaOH. The organic layer is washed with brine, dried over Na₂SO₄, and concentrated to give N-Boc-D-valinol as a clear oil. The material is used without chromatographic purification when 1H NMR shows the CH₂OH ABX pattern at 3.50–3.70 ppm and no carboxylic acid carbonyl signal.

The N-Boc-D-valinol is dissolved in TFA/DCM 1:1 at 0°C for 30 min. Concentration under reduced pressure gives D-valinol trifluoroacetate, which is partitioned between DCM and 2 M NaOH to liberate the free amino alcohol. The DCM layer is dried over Na₂SO₄ and concentrated below 25°C to avoid evaporative loss of the low-molecular-weight amino alcohol. D-valinol is hygroscopic and is cyclized immediately.

D-valinol (1.0 equiv) is dissolved in DCM at 0.3 M with triethylamine (3.0 equiv) and cooled to 0°C. A solution of triphosgene (0.35 equiv) in DCM is added over 45 min. The mixture is stirred for 2 h at 0°C and 1 h at 20°C, then quenched with 1 M HCl at 0°C. The organic phase is washed with 0.5 M NaHCO₃ and brine, dried, and concentrated. Flash chromatography on silica gel with hexane/ethyl acetate 4:1 elutes 4-isopropyloxazolidin-2-one as a crystalline solid. The melting point is measured by USP <741>, and the structure is confirmed by NMR per USP <761>.

The recovered oxazolidinone is acylated with propionyl chloride under n-butyllithium in THF at -78°C to produce the N-propionyl chiral auxiliary. Enolate formation with LDA (1.1 equiv) at -78°C and subsequent alkylation with an electrophile are monitored by chiral HPLC under USP <621> after auxiliary cleavage. Stereoselectivity is reported as an area ratio of the major to minor diastereomer at 210 nm. The N-Boc-D-valinol intermediate is stored at 2–8°C under nitrogen; extended exposure to ambient air leads to slow oxidation of the primary alcohol to the aldehyde.

In peptidomimetic stability programs, BOC-D-valine is used to replace L-valine at P2 or P3 positions in linear peptide leads. The protected monomer is anchored to 2-chlorotrityl chloride resin via carboxylate displacement with DIEA (3.0 equiv) in DCM at 25°C for 2 h, giving a loading of 0.6–0.8 mmol/g after capping with methanol. Chain elongation uses HATU/HOAt/DIEA (3.0/3.0/6.0 equiv) in DMF, with BOC-D-valine introduced as the second residue to maintain activation efficiency in the presence of the bulky isopropyl chain. Cleavage uses 20% hexafluoroisopropanol in DCM; the protected linear product is purified by preparative HPLC. The resulting D-Val-containing peptidomimetic is lyophilized and submitted to stability testing.

Stability is measured in pooled human serum filtered through a 0.2 μm membrane and equilibrated at 37°C under 5% CO₂. Aliquots are removed at 0, 2, 6, 24 h, precipitated with acetonitrile containing an internal standard, and analyzed by LC-MS/MS on a 2.1 × 50 mm, 1.7 μm C18 column using a 0.1% formic acid/acetonitrile gradient. Half-life values are calculated by nonlinear regression and reported with 95% confidence intervals from triplicate runs. No formal ASTM or ISO method covers ex vivo serum stability of peptidomimetics; therefore, comparator-controlled data are mandatory. Published stability data for BOC-D-valine-derived peptidomimetics are limited to specific protease families; the observed half-life shift is not transferable across sequences without kinetic confirmation. Residual DMF and acetonitrile are measured by USP <467>, with DMF limited to 880 ppm under ICH Q3C Class 2 concentration limits.

Macrocyclic Depsipeptide Assembly with Alternating D-Valine Residues

Valinomycin-type macrocyclic depsipeptides require an alternating sequence of L-valine, D-valine, D-hydroxyisovaleric acid, and L-lactic acid building blocks. This alternating ester–amide backbone is incompatible with standard homodetic peptide synthesis; BOC-D-valine supplies the protected D-valine carboxylic acid for ester bond formation to hydroxy acid termini. In a representative fragment assembly, BOC-D-valine (1.2 equiv) is coupled to L-lactic acid benzyl ester (1.0 equiv) in DCM at 0°C with DIC (1.5 equiv) and DMAP (0.1 equiv) for 12 h. The mixture is quenched with 0.5 M HCl, washed with brine, dried over MgSO₄, and concentrated to give the ester-linked BOC-D-Val-L-Lac-OBn intermediate. The BOC group is removed with TFA/DCM 1:1, and the resulting amino fragment is used directly in the next amide or ester coupling step.

Macrocyclization is conducted at high dilution because the D-valine β-branch retards intramolecular ring closure and promotes oligomerization. A linear depsipeptide precursor (1.0 equiv) is activated with HATU (1.2 equiv) and DIEA (3.0 equiv) in DCM at a substrate concentration of 0.002 M. The batch is stirred at 20°C for 20 h, with reaction monitoring by LC-MS. The cyclic product is purified by preparative HPLC on C18 silica with a water/acetonitrile gradient; D-valine incorporation is confirmed by acid hydrolysis and chiral HPLC under USP <621> at 210 nm. The DIC/DMAP esterification route is limited to hydroxy acid partners; coupling to free amines proceeds through the mixed anhydride method used in solution-phase fragment assembly to avoid DMAP-catalyzed racemization.

When Process-Grade Specifications Dictate Residual Solvent and Chiral Purity Limits

For downstream peptide manufacturers, BOC-D-valine is released into GMP production only after confirmatory tests for enantiomeric purity, residual solvents, and elemental impurities. Specific rotation is measured as a 1.0% solution in methanol at 20°C in a polarimeter cell of 100 mm path length under USP <781>; acceptance is established relative to a qualified D-enantiomer reference standard, and any excursion outside the assigned rotation window triggers chiral HPLC review. This two-stage optical and chromatographic evaluation is required because optical rotation alone cannot quantify low-level L-Val contamination that may arise from incomplete resolution during manufacture.

Storage boundaries are part of the release documentation. BOC-D-valine is stored at 2–8°C in double polyethylene bags inside a sealed aluminum foil laminate under nitrogen. The BOC group undergoes slow acid-catalyzed deprotection in humid air, generating isobutylene and carbon dioxide; open-container residence at relative humidity above 60% is limited to 30 min in segregated sampling booths. Incompatibilities include strong mineral acids, which liberate free D-valine, and primary amines at elevated temperatures, which form amides without prior activation. These controls are enforced in warehouse and dispensing SOPs under 21 CFR 211.160 for laboratory controls and ICH Q7 for materials management.